Ramesh Kaul, MD
Pulmonary Disease · New Castle, PANPI 1073563466
Payments from drug & device makers
Across 135 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$560
- AstraZeneca$350
- Regeneron Healthcare Solutions, Inc.$330
- Boehringer Ingelheim$326
- Takeda Pharmaceuticals U.S.A., Inc.$140
- Sanofi$131
- plus $792 from 18 others
What the payments were for
- Food & beverage$2,37590%
- Education$25310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $560 |
| AstraZeneca | 15 | $350 |
| Regeneron Healthcare Solutions, Inc. | 16 | $330 |
| Boehringer Ingelheim | 15 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $140 |
| Sanofi | 7 | $131 |
| Jazz Pharmaceuticals Inc. | 4 | $126 |
| Mallinckrodt Hospital Products Inc. | 3 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Amgen | 4 | $76 |
| Novartis | 3 | $66 |
| United Therapeutics Corporation | 5 | $63 |
| Pfizer | 3 | $56 |
| Harmony Biosciences LLC | 3 | $54 |
| Verona Pharma, Inc. | 2 | $36 |
| Electromed, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Insmed, Inc. | 1 | $13 |
How this compares
$2,628 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 924 | $618,484 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 36 | $618,463 |
| XolairOmalizumab | 36 | $157,522 |
| Breo ElliptaFluticasone/Vilanterol | 248 | $100,550 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 156 | $98,629 |
| EliquisApixaban | 227 | $82,792 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 131 | $76,323 |
| NuplazidPimavanserin Tartrate | 23 | $62,696 |
| Spiriva RespimatTiotropium Bromide | 84 | $51,553 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $43,533 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 72 | $40,207 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 930 | $30,590 |
| PrezcobixDarunavir/Cobicistat | 20 | $28,297 |
| JardianceEmpagliflozin | 60 | $25,033 |
| TrulicityDulaglutide | 63 | $20,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $560 | $788,1081,335 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat, Jardiance | $326 | $193,117347 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $350 | $112,897198 claims |
| PfizerEliquis | $56 | $82,792227 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $14 | $48,71290 claims |
| Lilly USA, LLCTrulicity | $19 | $20,66563 claims |
| NovartisEntresto | $66 | $15,54549 claims |
| AbbVieNamzaric, Linzess | $17 | $14,32537 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $140 | $6,20625 claims |
| MerckDulera | $14 | $4,59013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in New Castle
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.